irinotecan has been researched along with Leukemia, Myeloid, Acute in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Jiang, Z; Liu, J; Liu, Q; Wang, A; Wang, L; Wang, W; Yu, K; Zou, F | 1 |
| Bohnenberger, H; Farin, HF; Gerlach, K; Godavarthy, PS; Hoang, VT; Krause, DS; Llavona, P; Michels, BE; Müller-Kuller, U; Oehler, VG; Oellerich, T; Steiner, M; Verma, D; Voutsinas, JM; Wachter, A; Weissenberger, E; Zörnig, M | 1 |
| Akiyama, H; Kurosu, T; Miura, O; Murakami, N; Sakashita, C; Umezawa, Y; Yamamoto, M | 1 |
| Bourhis, JH; Damaj, G; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Ravoet, C; Ribrag, V; Suzan, F; Vantelon, JM | 1 |
| Baer, MR; Conroy, JM; Li, S; McQuaid, D; Minderman, H; Nowak, NJ; O'Loughlin, KL; Pendyala, L; Quinn, P | 1 |
| Caron, P; Liu, D; Patel, S; Seiter, K | 1 |
| Masaoka, T; Ohashi, Y; Ohno, R; Okada, K; Ota, K; Shirakawa, S; Taguchi, T | 1 |
| Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y | 1 |
3 trial(s) available for irinotecan and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Blast Crisis; Bone Marrow; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Time Factors | 2003 |
[Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
5 other study(ies) available for irinotecan and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Child, Preschool; DNA Damage; DNA Repair; Down-Regulation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Irinotecan; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Mitosis; Primary Cell Culture; Protein Kinase Inhibitors; Tandem Repeat Sequences; Topoisomerase I Inhibitors; Tretinoin; Xenograft Model Antitumor Assays | 2020 |
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
Topics: Animals; Apoptosis; Bone Marrow Transplantation; Cell Cycle; Disease Models, Animal; DNA Damage; DNA-Binding Proteins; Humans; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; RNA-Binding Proteins; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2019 |
Therapy-related leukemia with Inv(16)(p13.1q22) and type D CBFB/MYH11 developing after exposure to irinotecan-containing chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoradiotherapy; Chromosomes, Human, Pair 16; Female; Humans; Irinotecan; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Treatment Outcome | 2015 |
In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.
Topics: Apoptosis; Camptothecin; Cell Cycle; Cluster Analysis; DNA, Complementary; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Irinotecan; Kinetics; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; RNA, Messenger; Transcription, Genetic; Up-Regulation | 2005 |
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 2007 |